Phase 2 N=171 To Evaluate the Efficacy and Safety of 1146A Nasal Spray in Adult Participants With Symptoms of Common Cold
Common Cold
Primary: Average Nasal Symptom Score Over Days 1-4 (ANSS1-4) — 3.428; 3.336 Score on a scale — p=0.516
Clinical Trial Search
Completed trials with posted results — search by concept, filter by the parameters that matter at the bedside.
Phase 2 N=267 Phase II Study of MEDI4736, Tremelimumab, and MEDI4736 in Combination w/ Tremelimumab Squamous Cell Carcinoma of the Head and Neck
Recurrent/Metastatic Squamous Cell Carcinoma of Head & Neck
Primary: Objective Response Rate at 6 Months — 7.7; 9.2; 1.6 % participants
Phase 2 N=609 A Study to Assess the Long-term Safety and Efficacy of Erenumab (AMG 334) in Chronic Migraine Prevention.
Treatment for Prevention of Chronic Migraine
Primary: Number of Participants With Adverse Events — 398; 302; 34; 0 Participants
Phase 2 N=13 Study of the Safety, Pharmacodynamics (PD) and Efficacy of KRN23 in Children From 1 to 4 Years Old With X-linked Hypophosphatemia (XLH)
X-Linked Hypophosphatemia
Primary: Change From Baseline at Week 40 in Serum Phosphorus — 0.96 mg/dL — p=< 0.0001
Phase 2 N=32 A Study to Evaluate the Safety and Effect of Treatment With Experimental Antiviral Drugs in Combination With Peginterferon Alpha-2a and Ribavirin in People With Hepatitis C Virus Who Did Not Respond to Treatment in a Previous AbbVie/Abbott Combination Study
Chronic Hepatitis C
Primary: Percentage of Participants Achieving Sustained Virologic Response 12 Weeks Post Treatment (SVR12) — 81.3 percentage of participants
Phase 2 N=31 Interleukin-1 Blockade in HF With Preserved EF
Heart Failure With Normal Ejection Fraction
Primary: Change in Aerobic Exercise Capacity — -0.2; 1.0 ml/kg/min
Phase 2 N=158 A Study of MHAA4549A in Combination With Oseltamivir Versus Oseltamivir in Participants With Severe Influenza A Infection
Influenza
Primary: Percentage of Participants With Adverse Events — 80.4; 67.3; 74.5 percentage of participants
Phase 2 N=112 Phase II Study of MEDI4736 Monotherapy in Treatment of Recurrent or Metastatic Squamous Cell Carcinoma of the Head and Neck
Recurrent or Metastatic PD-L1-positive Squamous Cell Carcinoma of the Head and Neck
Primary: Objective Response Rate (ORR) — 16.2; 14.6; 18.9; 10.0 % of participants
Phase 2 N=21 Pregnenolone and Marijuana Dependence
Marijuana Dependence
Primary: Subjective Rating of Marijuana Craving on 1-7 Likert Scale — 1.64; 0.80 units on a scale
Phase 2 N=71 KW-0761 or Investigator's Choice in Subjects With Previously Treated Adult T-cell Leukemia-Lymphoma (ATL)
Adult T-cell Leukemia-Lymphoma
Primary: Overall Response Rate — 2; 0; 0; 0 participants
Phase 2 N=51 Prescription Opioid Abuse Among Pain Patients: Predictors of Relapse
Opioid Dependence
Primary: Number of Participants Retained in Study — 18 participants
Phase 2 N=714 Phase II HDM-SPIRE Safety and Efficacy Study
Rhinoconjunctivitis
Primary: Combined Score of Symptoms and Allergy Medication — 1.69; 1.51; 1.40; 1.56 units on a scale
Phase 2 N=10 Study on the Effect of a Beta Blocker on Increased Sensitivity to Pain in Humans Caused by Opioids
Hyperalgesia
Primary: Percent Change From Baseline in Size (Area) of Secondary Hyperalgesia After Cessation of Remifentanil Infusion, a Measure of Opioid-induced Hyperalgesia (OIH). — -28…
Phase 2 N=25 A Extension Study to Evaluate Revusiran (ALN-TTRSC) in Patients With Transthyretin (TTR) Cardiac Amyloidosis
TTR-mediated Amyloidosis
Primary: Safety and Tolerability Results of Long-term Dosing With ALN-TTRSC (Revusiran) Transthyretin (TTR) Cardiac Amyloidosis Patients. — 25; 22; 18 Participants
Phase 2 N=12 Evaluate Whether Combination Therapy With Methotrexate and Raptiva in Psoriasis Patients is Safe and Increases Efficacy
Psoriasis
Primary: PASI -- Psoriasis Area and Severity Index